Liver cancer treatment, liver cancer-targeted drugs, a new combination of liver cancer drugs significantly prolong survival.
Cancer & rayuwa rayuwa
The number of people that survive for five years after being diagnosed with digestive system cancers seems to be particularly low in India compared to more advanced countries. Survival rates are just 19% for stomach cancer compared to 25-30% in most countries, with 58% surviving in South Korea. In India, the survival rate for ciwon daji is 37% while it is 50-59% in most countries and goes up to 65% in the US. Only 4% of ciwon daji patients survive for five years in India compared to 10 to 20% elsewhere. Survival rates have dipped in the case of rectal cancer in India.
Even in breast and ciwon daji na prostate, where medical advances have ensured that over 80% of patients survive in advanced countries, only about 60% of Indian patients survive. ovarian ciwon daji survival rates have declined in India from 23% in 1995-99 to 14% in 2005-09. cutar sankarar mahaifa survival rates are 46% compared to the global figure of 50%, but there is a slight decline in India from 47% in 2005. It is understood that there are one million new liver cancer patients worldwide each year, of which 55% are patients in China. About 110,000 people die of liver cancer each year in China, and the 5-year recurrence rate in China is as high as 70%. Liver cancer is highly malignant and highly contagious.
Alamomin farko na cutar kansa
1. Cough: The liver mass stimulates the diaphragm. During breathing, it causes a reflex in the lungs to cause a cough, or liver cancer has lung metastases that cause a cough.
2. Gajiya: Kwayoyin cutar kansa suna lalata aikin ajiyar hanta sannan kuma an rage samar da kuzarin jiki.
3. Rashin nauyi wanda ba a fayyace ba: Kwayoyin cutar kansa suna bukatar karfi da sinadarai fiye da na al'ada lokacin da ake ci gaba, wanda ke haifar da karancin abinci mai gina jiki a cikin jiki, don haka marasa lafiya ke nuna karuwar nauyi. Sauran cututtukan daji suma suna nuna alamun ɓarnatarwa.
4. Alamun cututtukan ciki: Cutar narkewar abinci tana faruwa. Kimanin kashi ɗaya bisa uku na marasa lafiya da ke fama da cutar hanta za su sami alamun alamun cututtukan cututtukan narkewa a farkon matakin rashin lafiya, kama da cututtukan ciki.
5. Fever: mostly cancerous fever, which is mainly caused by the release of pyrogens into human blood circulation after tumo nama necrosis.
6. Zubar da jini: cingam da jini, subcutaneous bruising da sauran alamu.
7. Pain: Hepatic pain occurs in most patients with advanced liver cancer.
Me yasa yawancin masu fama da cutar hanta a kasashe masu tasowa? Menene musabbabin ciwon hanta?
1. Alcoholism and alcoholic hepatitis: Alcohol and its toxic metabolite acetaldehyde can cause alcoholic fatty liver, alcoholic hepatitis, and even liver fibrosis and liver cancer.
2. Obesity and fatty liver: Obesity is one of the root causes of many chronic diseases. Obesity can cause fatty liver problems and even worsen into cirrhosis and liver cancer. Usually, pay attention to 7 points full of diet, good exercise habits, eat high fat and high sugar food lifestyle.
3. B / C viral hepatitis: Chronic hepatitis B and C are the main causes of liver cancer in the past, accounting for about 60 ~ 70%. With the full implementation of the hepatitis B vaccine for newborns, the proportion of hepatitis B infection has decreased. Hepatitis C was also very popular a few years ago. Hepatitis C is currently curable and the threat of viral hepatitis is decreasing.
Yaya za a hana kansar hanta daga sake dawowa?
1. Maganin karfafa aiki. Yin aikin tiyata da magunguna masu alaƙa na iya cire yawancin ƙwayoyin cuta, amma ba za a iya cire ƙwayoyin kansa gaba ɗaya. Ragowar kwayoyin cutar kansa suna da babban yiwuwar sake dawowa; sabili da haka, dole ne a yi aikin karfafawa cikin lokaci. Za'a iya amfani da magungunan gargajiyar kasar Sin da magungunan hanta da hanta na dogon lokaci.
2. Motsa jiki sosai don karfafa garkuwar ka da jure cuta.
3. Daidaitaccen abinci, karfafa abinci mai gina jiki, rage cin mai da rage shakar abubuwa masu guba.
4. Kiyaye tunani mai kyau, yawanci ka koya daidaita tunanin mutum da motsin zuciyar ka, cimma nasarar aiki da hutu, ka guji yawan aiki. Damuwa da gajiya na iya haifar da rauni na jiki, wanda ke haifar da ƙananan rigakafi da ƙananan rigakafi, wanda ke haifar da cutar kansa.
Yaya ake magance kansar hanta kuma menene sabbin magunguna?
Liver cancer treatment is mainly based on surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
Magunguna masu niyyar cutar kansa
| suna gama gari | Product name | Target | Lokaci zuwa kasuwa | China ta jera | Mai bincike na asali | Nau'in magani |
| Sorafenib | Nexavar, Dogemei | KIT, VEGFR, PDGFR | 2005 | A | Bayer | Kananan kwayoyi |
| Regorfenib | Stivarga | Multi-manufa | 2012 | babu | Bayer | Kananan kwayoyi |
| Ramucirumab | Cyramza | VEGFR2 | 2014 | A | Eli Lilly | MAb |
| Lenvatinib | Lenvima | Multi-manufa | 2015 | A | Isa | Kananan kwayoyi |
Haɗin atejizumab da bevacizumab sun fi magani ɗaya
Recently, the European Society of Oncology 2019 (Asian Congress) held in Singapore announced the phase III of the tumor immunotherapy Tecentriq (atezolizumab, atuzumab) combined with Avastin (bevacizumab) first-line treatment of hepatocellular carcinoma (HCC). Clinical study IMbrave150 (NCT03434379). Compared to sorafenib, the first-line combination of atrezumab and bevacizumab has statistically and clinically improved progression-free survival (PFS) and overall survival (OS). The risk of death was reduced by 42% in patients receiving combination therapy, and the progression-free survival rate was 41% (no progression or risk of death).
In addition, in December 2018, the US FDA approved atezolizumab combined with bevacizumab + chemotherapy (carboplatin and paclitaxel) as first-line treatment for adult patients with metastatic non-squamous cututtukan daji na kansa marasa kansar without EGFR or ALK genome tumor aberrations. Based on data from group B of the IMpower150 study, compared with bevacizumab + chemotherapy, atezolizumab combined with bevacizumab + chemotherapy significantly prolonged patient survival (19.2 months vs 14.7 months).
Atuzumab is a PD-L1 antibody and belongs to tumor immunotherapy. The drug can bind to a protein called PD-L1 expressed on tumor cells and tumor infiltrating immune cells, blocking it from PD-1 and B7. .1 receptor interactions. By inhibiting PD-1, atuzumab can activate T cells, which has the potential to be used as a basic combination therapy for cancer immunotherapy, targeted drugs and various cancer chemotherapy.
Bevacizumab shine mai hana angiogenesis wanda ke niyya ga ɗaurin haɓakar ƙarancin jijiyoyin jijiyoyin jiki (VEGF). VEGF tana taka muhimmiyar rawa a cikin angiogenesis da kiyayewa a cikin yanayin rayuwar ƙari. Avastin yana cutar da ƙwayar jini na ciwace-ciwacen ta hanyar kai tsaye ga VEGF, yana hana shi yin hulɗa tare da masu karɓa akan ƙwayoyin jijiyoyin jini. Jigilar jini na ƙari yana dauke da
mabuɗin ikon haɓakawa da ƙwarewar rayuwa.
Akwai tushen kimiyya mai karfi don hada atelizumab da bevacizumab, kuma haɗuwa da magungunan biyu na da ƙarfin ƙarfafa garkuwar jiki da ƙari. Baya ga tasirinsa na anti-angiogenic, bevacizumab na iya ƙara haɓaka atezumab don dawo da juriya ta jiki ta hanyar hana rigakafin rigakafi da ke da alaƙa da VEGF, haɓaka shigarwar ƙwayar T-cell, da ƙaddamar da martani na T-cell ga antigens ƙari. Rigakafin ciwon daji
